Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ExternalLink');" target='_blank' href="http://www.nexavar.com/">www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG.  Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing.
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... 26, 2011 Vapotherm announced today the launch ... specifically for homecare and other low acuity environments. ... and European markets. Vapotherm,s Flowrest® ... home and other extended care environments.  According to ...
... 26, 2011 Omnicell, Inc . (NASDAQ: ... medication and supply management solutions and analytics software ... Victoria Hospital (RVH) selected Omnicell G4 solutions ... by Omnicell,s hallmark flexibility and functionality, RVH became ...
Cached Medicine Technology:Vapotherm Announces Commercial Launch of Flowrest® Homecare Device 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... bring attention to the cancer risks associated with power ... to tell their story to federal regulators, as they ... U.S. Food & Drug Administration (FDA) advisory panel ... reports. According to the Rochester Democrat and Chronicle, ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
(Date:7/13/2014)... California (PRWEB) July 13, 2014 Celebrity ... Musico has formed a promotional partnership with Aqua Health ... based Omega-3 EPA supplement . The collaboration was ... a celebrity fitness trainer , actor, model, and ... go-to trainer for A-List celebrities, he has prepared stars ...
(Date:7/13/2014)... July 13, 2014 According to the ... this is a comprehensive guide that features a series ... with KP (keratosis pilaris). This guide consists of ... Is Keratosis Pilaris? ,     Chapter 2: What Cause ... If I Have KP? ,     Chapter 4: Keratosis ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3
... WASHINGTON, March 28 Thousands of epilepsy advocates, caregivers, ... celebrities at the nation,s Capitol today to support the ... two years, the event has raised more than $2 ... event is expected to increase those numbers significantly. Money ...
... could replace anti-clotting drug warfarin for many patients, researchers ... implanted device may soon replace the anti-clotting drug warfarin ... with atrial fibrillation, a new study suggests. , People ... stroke, the researchers noted, and typically need to take ...
... in era of rising costs , , FRIDAY, March 27 (HealthDay ... national health care reform when she was first lady in ... are working -- are without health insurance. , That finding ... a state-by-state picture of people foregoing insurance because of rising ...
... Drug-eluting stents were safe and superior to bare metal ... "real-world" patients enrolled in a nationwide registry of cardiovascular ... , The findings were presented today at the ... Scientific Session. They also appear online in the ...
... (NYSE: NUS ) announced that more than 100,000 ... the company,s distributors and customers who have purchased Epoch Baobab ... company has donated $0.25 from the sale of every Epoch ... Foundation,s Seeds of Hope reforestation project. "When someone purchases a ...
... Earnings Guidance to a Minimum of $0.25 per diluted ... Service Corporation (Nasdaq: PRSC ) today announced ... December 31, 2008. Included in the results is ... related to the Company,s intangible assets, which, when added ...
Cached Medicine News:Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 3Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3Health News:One in Five Working Adults Said to Lack Health Insurance 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 3Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 4Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 5Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 6Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 7Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 8Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 9Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 10Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 11Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 12Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 13Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 14
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
Medicine Products: